174 related articles for article (PubMed ID: 35501422)
1. Single-nucleotide polymorphisms and the effectiveness of taxane-based chemotherapy in premenopausal breast cancer: a population-based cohort study in Denmark.
Hjorth CF; Damkier P; Stage TB; Feddersen S; Hamilton-Dutoit S; Rørth M; Ejlertsen B; Lash TL; Ahern TP; Sørensen HT; Cronin-Fenton D
Breast Cancer Res Treat; 2022 Jul; 194(2):353-363. PubMed ID: 35501422
[TBL] [Abstract][Full Text] [Related]
2. The impact of single nucleotide polymorphisms on return-to-work after taxane-based chemotherapy in breast cancer.
Hjorth CF; Damkier P; Stage TB; Feddersen S; Hamilton-Dutoit S; Ejlertsen B; Lash TL; Bøggild H; Sørensen HT; Cronin-Fenton D
Cancer Chemother Pharmacol; 2023 Feb; 91(2):157-165. PubMed ID: 36598552
[TBL] [Abstract][Full Text] [Related]
3. Socioeconomic position and prognosis in premenopausal breast cancer: a population-based cohort study in Denmark.
Hjorth CF; Damkier P; Ejlertsen B; Lash T; Sørensen HT; Cronin-Fenton D
BMC Med; 2021 Sep; 19(1):235. PubMed ID: 34587961
[TBL] [Abstract][Full Text] [Related]
4. Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical Trial.
Sparano JA; Gray RJ; Makower DF; Albain KS; Saphner TJ; Badve SS; Wagner LI; Kaklamani VG; Keane MM; Gomez HL; Reddy PS; Goggins TF; Mayer IA; Toppmeyer DL; Brufsky AM; Goetz MP; Berenberg JL; Mahalcioiu C; Desbiens C; Hayes DF; Dees EC; Geyer CE; Olson JA; Wood WC; Lively T; Paik S; Ellis MJ; Abrams J; Sledge GW
JAMA Oncol; 2020 Mar; 6(3):367-374. PubMed ID: 31566680
[TBL] [Abstract][Full Text] [Related]
5. Genetic polymorphisms of autophagy-related gene 5 (ATG5) rs473543 predict different disease-free survivals of triple-negative breast cancer patients receiving anthracycline- and/or taxane-based adjuvant chemotherapy.
Li M; Ma F; Wang J; Li Q; Zhang P; Yuan P; Luo Y; Cai R; Fan Y; Chen S; Li Q; Xu B
Chin J Cancer; 2018 Jan; 37(1):4. PubMed ID: 29382381
[TBL] [Abstract][Full Text] [Related]
6. Predictive pharmacogenetic biomarkers for breast cancer recurrence prevention by simvastatin.
Ahern TP; Damkier P; Feddersen S; Kjærsgaard A; Lash TL; Hamilton-Dutoit S; Lythjohan CB; Ejlertsen B; Christiansen PM; Cronin-Fenton DP
Acta Oncol; 2020 Sep; 59(9):1009-1015. PubMed ID: 32351149
[No Abstract] [Full Text] [Related]
7. Taxane-containing regimens for metastatic breast cancer.
Ghersi D; Willson ML; Chan MM; Simes J; Donoghue E; Wilcken N
Cochrane Database Syst Rev; 2015 Jun; 2015(6):CD003366. PubMed ID: 26058962
[TBL] [Abstract][Full Text] [Related]
8. Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation.
Ward S; Simpson E; Davis S; Hind D; Rees A; Wilkinson A
Health Technol Assess; 2007 Oct; 11(40):1-144. PubMed ID: 17903394
[TBL] [Abstract][Full Text] [Related]
9. Drug metabolising enzyme polymorphisms and chemotherapy-related ovarian failure in young breast cancer survivors.
Charo LM; Homer MV; Natarajan L; Haunschild C; Chung K; Mao JJ; DeMichele AM; Su HI
J Obstet Gynaecol; 2021 Apr; 41(3):447-452. PubMed ID: 32496149
[TBL] [Abstract][Full Text] [Related]
10. Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer.
Zaheed M; Wilcken N; Willson ML; O'Connell DL; Goodwin A
Cochrane Database Syst Rev; 2019 Feb; 2(2):CD012873. PubMed ID: 30776132
[TBL] [Abstract][Full Text] [Related]
11. Taxanes for adjuvant treatment of early breast cancer.
Ferguson T; Wilcken N; Vagg R; Ghersi D; Nowak AK
Cochrane Database Syst Rev; 2007 Oct; (4):CD004421. PubMed ID: 17943815
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetics of taxane-induced neurotoxicity in breast cancer: Systematic review and meta-analysis.
Guijosa A; Freyria A; Espinosa-Fernandez JR; Estrada-Mena FJ; Armenta-Quiroga AS; Ortega-Treviño MF; Catalán R; Antonio-Aguirre B; Villarreal-Garza C; Perez-Ortiz AC
Clin Transl Sci; 2022 Oct; 15(10):2403-2436. PubMed ID: 35892315
[TBL] [Abstract][Full Text] [Related]
13. Metabolic Pathway Analysis and Effectiveness of Tamoxifen in Danish Breast Cancer Patients.
Ahern TP; Collin LJ; Baurley JW; Kjærsgaard A; Nash R; Maliniak ML; Damkier P; Zwick ME; Isett RB; Christiansen PM; Ejlertsen B; Lauridsen KL; Christensen KB; Silliman RA; Sørensen HT; Tramm T; Hamilton-Dutoit S; Lash TL; Cronin-Fenton D
Cancer Epidemiol Biomarkers Prev; 2020 Mar; 29(3):582-590. PubMed ID: 31932415
[TBL] [Abstract][Full Text] [Related]
14. Prospective evaluation of the drug-metabolizing enzyme polymorphisms and toxicity profile of docetaxel in Korean patients with operable lymph node-positive breast cancer receiving adjuvant chemotherapy.
Kim KP; Ahn JH; Kim SB; Jung KH; Yoon DH; Lee JS; Ahn SH
Cancer Chemother Pharmacol; 2012 May; 69(5):1221-7. PubMed ID: 22271208
[TBL] [Abstract][Full Text] [Related]
15. Classical CMF regimen as adjuvant chemotherapy for triple-negative breast cancer may be more effective compared with anthracycline or taxane-based regimens.
Wang S; Shi Y; Yuan Z; Wang X; Liu D; Peng R; Teng X; Qin T; Peng J; Lin G; Jiang X
Med Oncol; 2012 Jun; 29(2):547-53. PubMed ID: 21528408
[TBL] [Abstract][Full Text] [Related]
16. Cohort Profile: the Predictors of Breast Cancer Recurrence (ProBe CaRE) Premenopausal Breast Cancer Cohort Study in Denmark.
Collin LJ; Cronin-Fenton DP; Ahern TP; Christiansen PM; Damkier P; Ejlertsen B; Hamilton-Dutoit S; Kjærsgaard A; Silliman RA; Sørensen HT; Lash TL
BMJ Open; 2018 Aug; 8(7):e021805. PubMed ID: 30068618
[TBL] [Abstract][Full Text] [Related]
17. Anthracycline and taxane-based chemotherapy versus docetaxel and cyclophosphamide in the adjuvant treatment of HER2-negative breast cancer patients: a systematic review and meta-analysis of randomized controlled trials.
Caparica R; Bruzzone M; Poggio F; Ceppi M; de Azambuja E; Lambertini M
Breast Cancer Res Treat; 2019 Feb; 174(1):27-37. PubMed ID: 30465156
[TBL] [Abstract][Full Text] [Related]
18. Manganese superoxide dismutase and breast cancer recurrence: a Danish clinical registry-based case-control study, and a meta-analysis.
Cronin-Fenton DP; Christensen M; Lash TL; Ahern TP; Pedersen L; Garne JP; Ewertz M; Autrup H; Sørensen HT; Hamilton-Dutoit S
PLoS One; 2014; 9(1):e87450. PubMed ID: 24498107
[TBL] [Abstract][Full Text] [Related]
19. Association of cyclophosphamide drug-metabolizing enzyme polymorphisms and chemotherapy-related ovarian failure in breast cancer survivors.
Su HI; Sammel MD; Velders L; Horn M; Stankiewicz C; Matro J; Gracia CR; Green J; DeMichele A
Fertil Steril; 2010 Jul; 94(2):645-54. PubMed ID: 19376514
[TBL] [Abstract][Full Text] [Related]
20. Cyclophosphamide-metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study.
Gor PP; Su HI; Gray RJ; Gimotty PA; Horn M; Aplenc R; Vaughan WP; Tallman MS; Rebbeck TR; DeMichele A
Breast Cancer Res; 2010; 12(3):R26. PubMed ID: 20459744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]